Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 45, Issue 1 (Jan 2007)

Issues

Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update

Rita Passerini / Daniela Riggio / Michela Salvatici / Laura Zorzino / Davide Radice / Maria Teresa Sandri
Published Online: 2007-01-24 | DOI: https://doi.org/10.1515/CCLM.2007.003

Abstract

Background: CA 19-9 is a marker principally related to pancreatic and gall bladder cancer. Although its determination has no value in screening for these malignancies, it is used in post-operative monitoring and during chemotherapeutic treatment of confirmed disease. Measurements during follow-up must be comparable and must be performed with standard, validated methods.

Methods: We compared four routinely used analytical systems for CA 19-9 determination: the Architect i2000 and AxSYM systems from Abbott Laboratories, the Elecsys 1010 from Roche Diagnostics, and the KRYPTOR system from Brahms Diagnostics. We evaluated the analytical performance of the four systems and compared measurements of CA 19-9 values, which covered the whole analytical range.

Results: The analytical performance and accuracy of the four systems were fairly good, but Passing-Bablok regression and mountain plots showed significant differences in CA 19-9 values measured with the four platforms.

Conclusions: Our data indicate that during tumor follow-up, the use of the same system is appropriate to avoid the risk of a variation due to the method rather than the disease. Moreover, whenever a change in analytical equipment is required, careful analysis of CA 19-9 results must be undertaken.

Clin Chem Lab Med 2007;45:100–4.

Keywords: analytical performance; CA 19-9 determination; comparability; tumor marker

About the article

Corresponding author: Rita Passerini, DSc, Laboratory Medicine Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy Phone: +39-02-57489348, Fax: +39-02-57489417,


Received: June 16, 2006

Accepted: September 28, 2006

Published Online: 2007-01-24

Published in Print: 2007-01-01


Citation Information: Clinical Chemical Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2007.003.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Juliana C. Soares, Leonardo E. O. Iwaki, Andrey C. Soares, Valquiria C. Rodrigues, Matias E. Melendez, José Humberto T. G. Fregnani, Rui M. Reis, Andre L. Carvalho, Daniel S. Corrêa, and Osvaldo N. Oliveira
ACS Omega, 2017, Volume 2, Number 10, Page 6975
[2]
Anshu Thapa, Andrey Coatrini Soares, Juliana Coatrini Soares, Iram Taj Awan, Diogo Volpati, Matias Eliseo Melendez, José Humberto Tavares Guerreiro Fregnani, André Lopes Carvalho, and Osvaldo N. Oliveira
ACS Applied Materials & Interfaces, 2017, Volume 9, Number 31, Page 25878
[3]
Rita Passerini, Maria C. Cassatella, Sara Boveri, Michela Salvatici, Davide Radice, Laura Zorzino, Claudio Galli, and Maria T. Sandri
American Journal of Clinical Pathology, 2012, Volume 138, Number 2, Page 281
[4]
Brian B. Haab, Ying Huang, Seetharaman Balasenthil, Katie Partyka, Huiyuan Tang, Michelle Anderson, Peter Allen, Aaron Sasson, Herbert Zeh, Karen Kaul, Doron Kletter, Shaokui Ge, Marshall Bern, Richard Kwon, Ivan Blasutig, Sudhir Srivastava, Marsha L. Frazier, Subrata Sen, Michael A. Hollingsworth, Jo Ann Rinaudo, Ann M. Killary, Randall E. Brand, and Zoltán Rakonczay
PLOS ONE, 2015, Volume 10, Number 10, Page e0139049
[5]
G. Erden, A. O. Barazi, G. Tezcan, and M. M. Yildirimkaya
Scandinavian Journal of Clinical and Laboratory Investigation, 2008, Volume 68, Number 3, Page 212
[6]
Johan Bjerner, Anita Høgetveit, Katrine Wold Akselberg, Kirsti Vangsnes, Elisabeth Paus, Trine Bjøro, Ole Petter Børmer, and Kjell Nustad
Scandinavian Journal of Clinical and Laboratory Investigation, 2008, Volume 68, Number 8, Page 703
[7]
Andrey C. Soares, Juliana C. Soares, Flavio M. Shimizu, Matias E. Melendez, André L. Carvalho, and Osvaldo N. Oliveira
ACS Applied Materials & Interfaces, 2015, Volume 7, Number 46, Page 25930
[8]
Julien Marlet and Maguy Bernard
Journal of Clinical Laboratory Analysis, 2016, Volume 30, Number 1, Page 5
[9]
M. Ventrucci, P. Pozzato, A. Cipolla, and G. Uomo
Digestive and Liver Disease, 2009, Volume 41, Number 5, Page 357
[10]
Kristina Hotakainen, Pirjo Tanner, Henrik Alfthan, Caj Haglund, and Ulf-Håkan Stenman
Clinica Chimica Acta, 2009, Volume 400, Number 1-2, Page 123
[11]
Romolo M. Dorizzi, Sandra Meneghelli, Maria Rocca, and Anna Ferrari
Clinical Chemical Laboratory Medicine, 2007, Volume 45, Number 7

Comments (0)

Please log in or register to comment.
Log in